Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Varlirix (GlaxoSmithKline).

¹Stanford University, CA 94305-5208, USA. AArvin@Stanford.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|August 21, 2002

Summary

This summary is machine-generated.

GlaxoSmithKline developed Varilrix, a live, attenuated Oka-strain varicella zoster virus vaccine for preventing chickenpox infections. This vaccine became available in Europe and India by 1998, expanding to Brazil and Hong Kong by 2001.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cryogenic electron tomography reveals herpesvirus capsid assembly intermediates inside the cell nucleus.

Nature communications·2026

Same author

Cryogenic Electron Tomography Redefines Herpesvirus Capsid Assembly Intermediates Inside the Cell Nucleus.

bioRxiv : the preprint server for biology·2025

Same author

Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states.

Nature communications·2023

Same author

Creating the "Dew Drop on a Rose Petal": the Molecular Pathogenesis of Varicella-Zoster Virus Skin Lesions.

Microbiology and molecular biology reviews : MMBR·2023

Same author

Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.

The Journal of infectious diseases·2022

Same author

Modulation of Host Cell Signaling Pathways by Varicella-Zoster Virus.

Current topics in microbiology and immunology·2022

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Virology
Immunology
Vaccinology

Background:

Varicella zoster virus (VZV) causes chickenpox, a common and contagious childhood illness.
Effective immunization strategies are crucial for public health to prevent VZV infections.
The development of live, attenuated viral vaccines has been a significant advancement in infectious disease control.

Purpose of the Study:

To introduce Varilrix, a novel vaccine preparation for immunization against varicella zoster virus infections.
To document the development and initial market launch of the Varilrix vaccine by GlaxoSmithKline.

Main Methods:

Development of a live, attenuated vaccine using the Oka strain of varicella zoster virus.
Formulation and preparation of the Varilrix vaccine for administration.

Related Experiment Videos

Main Results:

Varilrix, a live, attenuated Oka-strain VZV vaccine, was successfully developed and launched by GlaxoSmithKline.
The vaccine achieved market availability in several European countries and India by the end of 1998.
Further market expansion occurred by 2001, with Varilrix becoming available in Brazil and Hong Kong.

Conclusions:

Varilrix represents a significant development in the prevention of varicella zoster virus infections.
The vaccine's progressive market introduction demonstrates its accessibility in various global regions.
The availability of Varilrix contributes to public health efforts in controlling chickenpox outbreaks.